Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2019 | Pages:
103 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global psoriatic arthritis treatment market size is expected to reach over USD 18.6 billion by 2026, according to a new study by Grand View Research Inc. It is projected to expand at a CAGR of 10.1% during the forecast period. Emergence of biosimilars, new product launches, and a rising consumer awareness are some of the key factors driving the growth. Biologics generated the highest revenue among other drug classes, in 2018. The segment growth is driven by the demand for targeted therapy, improved safety & efficacy profiles, anticipated launches of several promising pipeline candidates, and strong commercial performances of existing products. DMARDs is also expected to maintain a steady growth rate, supported by the first-line action of corticosteroids as well as the impending launch of JAK-inhibitors and TYK2 kinase inhibitors. North America captured the highest market share in 2018, propelled by high healthcare expenditure, disease prevalence, regional presence of key manufacturers, and rapid rise in consumer awareness. Asia Pacific is expeted to demonstrate the fastest regional growth over the forecast period, driven by a rising trend of biosimilars, improvement in healthcare infrastructure, and increasing disposable income. Some key players in the psoriatic arthritis (PsA) treatmentmarket include AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; AstraZeneca plc; Bausch Health Companies Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Novartis International AG; Eli Lilly and Company; Pfizer, Inc.; and UCB S.A. Further key findings from the study suggest: • Biologics captured over 50% share of the psoriatic arthritis treatment market in 2018. The segment is anticipated to witness growth, attributed to the launch of infliximab, guselkumab, bimekizumab, risankizumab, and tildrakizumab • Upadacitinib, filgotinib, and BMS-986165 -upon launch - are likely to have a positive impact on the growth rate of DMARDs • Injectables accounted for the largest PsA treatment market share among other routes of administration in 2018 • North America and Europe, collectively, captured more than half the revenue share in 2018 and are anticipated to witness significant growth in the forthcoming years
Table of Contents
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR's internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.3.5.1 Data for primary interviews in North america
1.3.5.2 Data for primary interviews in Europe
1.3.5.3 Data for primary interviews in Asia Pacific
1.3.5.4 Data for primary interviews in Middle East and Africa
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume price analysis (Model 2)
1.6.2.1 Approach 2: Volume price analysis
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Psoriatic Arthritis Treatment Market Variables, Trends & Scope
3.1 Disease Primer and Epidemiology
3.2 Market Lineage Outlook
3.2.1 Parent market outlook
3.2.2 Ancillary market outlook
3.3 Penetration & Growth Prospect Mapping
3.4 Product Pipeline Analysis, by Stage
3.5 User Perspective Analysis
3.5.1 Consumer Behavior Analysis
3.6 List of Key End Users
3.7 Regulatory Framework
3.8 Market Dynamics
3.8.1 Market drivers analysis
3.8.1.1 Emergence of biosimilars
3.8.1.2 Strong product pipeline
3.8.1.3 New product lauches
3.8.1.4 Increasing disease prevalence
3.8.1.5 Proactive government initiatives
3.8.2 Market restraints analysis
3.8.2.1 Stringent regulatory approval
3.8.2.2 High cost of treatment
3.8.2.3 Adverse effect of drugs
3.9 Psoriatic Arthritis: Market Analysis Tools
3.9.1 Industry analysis - Porter's
3.9.2 PESTLE analysis
3.9.3 Major deals and strategic alliances
3.9.3.1 New Product Launch
3.9.3.2 Acquisition
3.9.3.3 Expansion
3.9.3.4 Partnerships
3.9.3.5 Marketing & Promotions
Chapter 4 Psoriatic Arthritis Treatment Market: Segment Analysis, By Drug Class, 2014 - 2026 (USD Million)
4.1 Definition and Scope
4.2 Drug Class Type Market Share Analysis, 2018 & 2026
4.3 Segment Dashboard
4.4 Global Psoriatic Arthritis Market, by Drug Class, 2014 to 2026
4.5 Market Size & Forecasts and Trend Analyses, 2014 to 2026
4.5.1 NSAIDs
4.5.1.1 NSAIDs market, 2014 - 2026 (USD Million)
4.5.2 DMARDs
4.5.2.1 DMARDs market, 2014 - 2026 (USD Million)
4.5.3 Biologics
4.5.3.1 Biologics market, 2014 - 2026 (USD Million)
4.5.4 Others
4.5.4.1 Others market, 2014 - 2026 (USD Million)
Chapter 5 Psoriatic Arthritis Treatment Market: Segment Analysis, By Product Type, 2014 - 2026 (USD Million)
5.1 Definition and Scope
5.2 Product Type Market Share Analysis, 2018 & 2026
5.3 Segment Dashboard
5.4 Global Psoriatic Arthritis Market, by Product Type, 2014 to 2026
5.5 Market Size & Forecasts and Trend Analyses, 2014 to 2026
5.5.1 Prescription
5.5.1.1 Prescription market, 2014 - 2026 (USD Million)
5.5.2 OTC
5.5.2.1 OTC market, 2014 - 2026 (USD Million)
Chapter 6 Psoriatic Arthritis Treatment Market: Segment Analysis, By Route of Administration, 2014 - 2026 (USD Million)
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2018 & 2026
6.3 Segment Dashboard
6.4 Global Psoriatic Arthritis Market, by Route of Administration, 2014 to 2026
6.5 Market Size & Forecasts and Trend Analyses, 2014 to 2026
6.5.1 Topical
6.5.1.1 Topical market, 2014 - 2026 (USD Million)
6.5.2 Oral
6.5.2.1 Oral market, 2014 - 2026 (USD Million)
6.5.3 Injectable
6.5.3.1 Injectable market, 2014 - 2026 (USD Million)
Chapter 7 Psoriatic Arthritis Treatment Market: Regional Market Analysis, 2014 - 2026 (USD Million)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2018 & 2026
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Regional Market Share and Leading Players, 2018
7.5.1 North america
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 Middle East and Africa
7.6 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.6.1 North America
7.6.2 Europe
7.6.3 Asia Pacific
7.6.4 Latin America
7.6.5 Middle East and Africa
7.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2018 to 2026
7.7.1 North America
7.7.1.1 North America market estimates and forecast, 2014 - 2026 (USD Million)
7.7.1.2 U.S.
7.7.1.2.1 U.S. Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.1.3 Canada
7.7.1.3.1 Canada Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.2 Europe
7.7.2.1 Europe Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.2.2 U.K.
7.7.2.2.1 U.K. Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.2.3 Germany
7.7.2.3.1 Germany Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.2.4 Spain
7.7.2.4.1 Spain Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.2.5 France
7.7.2.5.1 France Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.2.6 Italy
7.7.2.6.1 Italy Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.3 Asia Pacific
7.7.3.1 Asia Pacific Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.3.2 Japan
7.7.3.2.1 Japan Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.3.3 China
7.7.3.3.1 China Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.3.4 India
7.7.3.4.1 India Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.3.5 South Korea
7.7.3.5.1 South Korea Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.3.6 Australia
7.7.3.6.1 Australia Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.4 Latin America
7.7.5 Latin America Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.5.1 Brazil
7.7.5.1.1 Brazil Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.5.2 Mexico
7.7.5.2.1 Mexico Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.5.3 Argentina
7.7.5.3.1 Argentina Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.6 MEA
7.7.6.1 MEA Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.6.2 South Africa
7.7.6.2.1 South Africa Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.6.3 Saudi Arabia
7.7.6.3.1 Saudi Arabia Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
7.7.6.4 UAE
7.7.6.4.1 UAE Psoriatic Arthritis treatment market, 2014 - 2026 (USD Million)
Chapter 8 Psoriatic Arthritis treatment market - Competitive Analysis
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix
8.1.2 Heat map analysis
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List of key distributors and channel partners
8.3.2 Key customers
8.3.3 Key company market share analysis, 2018
8.4 Public Companies
8.4.1 Company market position analysis
8.4.2 Company Market Share, by region
8.4.3 Competitive Dashboard Analysis
8.5 Private Companies
8.5.1 List of key emerging companies
8.5.3 Regional network map
8.5.4 Company market position analysis
8.6 Supplier Ranking
8.7 Company Profiles
8.7.1 AbbVie, Inc.
8.7.1.1 Company overview
8.7.1.2 Financial performance
8.7.1.3 Product benchmarking
8.7.1.4 Strategic initiatives
8.7.2 Amgen, Inc.
8.7.2.1 Company overview
8.7.2.2 Financial performance
8.7.2.3 Product benchmarking
8.7.2.4 Strategic initiatives
8.7.3 Johnson & Johnson Services, Inc.
8.7.3.1 Company overview
8.7.3.2 Financial performance
8.7.3.3 Product benchmarking
8.7.3.4 Strategic initiatives
8.7.4 Bristol-Myers Squibb Company
8.7.4.1 Company overview
8.7.4.2 Financial performance
8.7.4.3 Product benchmarking
8.7.4.4 Strategic initiatives
8.7.5 Celgene Corporation
8.7.5.1 Company overview
8.7.5.2 Financial performance
8.7.5.3 Product benchmarking
8.7.5.4 Strategic initiatives
8.7.6 Novartis International AG
8.7.6.1 Company overview
8.7.6.2 Financial performance
8.7.6.3 Product benchmarking
8.7.6.4 Strategic initiatives
8.7.7 Eli Lilly and Company
8.7.7.1 Company overview
8.7.7.2 Financial performance
8.7.7.3 Product benchmarking
8.7.7.4 Strategic initiatives
8.7.8 Pfizer, Inc.
8.7.8.1 Company overview
8.7.8.2 Product benchmarking
8.7.8.3 Strategic initiatives
8.7.9 UCB S.A.
8.7.9.1 Company overview
8.7.9.2 Financial performance
8.7.9.3 Product benchmarking
8.7.9.4 Strategic initiatives
8.7.10 AstraZeneca plc
8.7.10.1 Company overview
8.7.10.2 Financial performance
8.7.10.3 Product benchmarking
8.7.10.4 Strategic initiatives
Chapter 9 Recommendations
List of Tables Table 1 Primary interview details: North America Table 2 Primary interview details: Europe Table 3 Primary interview details: Asia Pacific Table 4 Primary interview details: Middle East and Africa Table 5 List of secondary sources Table 6 List of abbreviations Table 7 Psoriatic Arthritis Epidemiology- 2018 (%) Table 8 Product pipeline Table 9 Regulatory framework Table 10 North America psoriatic arthritis treatment, by country, 2014 - 2026 (USD Million) Table 11 North America psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 12 North America psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 13 North America psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 14 U.S. psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 15 U.S. psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 16 U.S. psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 17 Canada psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 18 Canada psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 19 Canada psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 20 Europe psoriatic arthritis treatment, by country, 2014 - 2026 (USD Million) Table 21 Europe psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 22 Europe psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 23 Europe psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 24 U.K. psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 25 U.K. psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 26 U.K. psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 27 Germany psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 28 Germany psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 29 Germany psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 30 Spain psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 31 Spain psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 32 Spain psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 33 France psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 34 France psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 35 France psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 36 Italy psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 37 Italy psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 38 Italy psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 39 Asia Pacific psoriatic arthritis treatment, by country, 2014 - 2026 (USD Million) Table 40 Asia Pacific psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 41 Asia Pacific psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 42 Asia Pacific psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 43 Japan psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 44 Japan psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 45 Japan psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 46 China psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 47 China psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 48 China psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 49 India psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 50 India psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 51 India psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 52 South Korea psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 53 South Korea psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 54 South Korea psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 55 Australia psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 56 Australia psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 57 Australia psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 58 Latin America psoriatic arthritis treatment, by country, 2014 - 2026 (USD Million) Table 59 Latin America psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 60 Latin America psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 61 Latin America psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 62 Brazil psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 63 Brazil psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 64 Brazil psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 65 Mexico psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 66 Mexico psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 67 Mexico psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 68 Argentina psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 69 Argentina psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 70 Argentina psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 71 MEA psoriatic arthritis treatment, by country, 2014 - 2026 (USD Million) Table 72 MEA psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 73 MEA psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 74 MEA psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 75 South Africa psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 76 South Africa psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 77 South Africa psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 78 Saudi Arabia psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 79 Saudi Arabia psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 80 Saudi Arabia psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million) Table 81 UAE psoriatic arthritis treatment, by drug class, 2014 - 2026 (USD Million) Table 82 UAE psoriatic arthritis treatment, by product type, 2014 - 2026 (USD Million) Table 83 UAE psoriatic arthritis treatment, by RoA, 2014 - 2026 (USD Million)
List of Figures Fig. 1 Psoriatic arthritis treatment market segmentation Fig. 2 Market research process Fig. 3 Information procurement Fig. 4 Primary research pattern Fig. 5 Primary interviews in North America Fig. 6 Primary interviews in Europe Fig. 7 Primary interviews in Asia Pacific Fig. 8 Primary interviews in Middle East and Africa Fig. 9 Market research approaches Fig. 10 Value-chain-based sizing & forecasting Fig. 11 QFD modeling for market share assessment Fig. 12 Market formulation & validation Fig. 13 Market outlook (2018) Fig. 14 Segment Outlook (Drug Class, 2018) Fig. 15 Strategy framework Fig. 16 Psoriatic arthritis epidemiology- 2018 Fig. 17 Penetration & growth prospect mapping Fig. 18 Consumer behavior analysis Fig. 19 Market driver relevance analysis (Current & future impact) Fig. 20 Market restraint relevance analysis (Current & future impact) Fig. 21 Porter's five forces analysis Fig. 22 PESTLE analysis Fig. 23 Strategy mapping Fig. 24 Psoriatic arthritis treatment market: Drug class movement analysis Fig. 25 Drug class segment dashboard Fig. 26 Psoriatic arthritis treatment market drug class outlook: Key takeaways Fig. 27 NSAIDs market, 2014 - 2026 (USD Million) Fig. 28 DMARDs market, 2014 - 2026 (USD Million) Fig. 29 Biologics market, 2014 - 2026 (USD Million) Fig. 30 Others market, 2014 - 2026 (USD Million) Fig. 31 Psoriatic arthritis treatment market: Product type movement analysis Fig. 32 Product type segment dashboard Fig. 33 Psoriatic arthritis treatment market product type outlook: Key takeaways Fig. 34 Prescription market, 2014 - 2026 (USD Million) Fig. 35 OTC market, 2014 - 2026 (USD Million) Fig. 36 Psoriatic arthritis treatment market: Route of administration movement analysis Fig. 37 RoA segment dashboard Fig. 38 Psoriatic arthritis treatment market RoA outlook: Key takeaways Fig. 39 Topical market, 2014 - 2026 (USD Million) Fig. 40 Oral market, 2014 - 2026 (USD Million) Fig. 41 Injectable market, 2014 - 2026 (USD Million) Fig. 42 Regional outlook, 2018 & 2026 Fig. 43 Regional market dashboard Fig. 44 Regional market place: Key takeaways Fig. 45 North America market share and leading players (2018) Fig. 46 Europe market share and leading players (2018) Fig. 47 Asia Pacific market share and leading players (2018) Fig. 48 Latin America market share and leading players (2018) Fig. 49 Middle East and Africa market share and leading players (2018) Fig. 50 North America, SWOT Fig. 51 Europe, SWOT Fig. 52 Asia Pacific,, SWOT Fig. 53 Latin America, SWOT Fig. 54 Middle East and Africa, SWOT Fig. 55 North America Fig. 56 North America psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 57 U.S. Fig. 58 U.S. psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 59 Canada Fig. 60 Canada psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 61 Europe Fig. 62 Europe psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 63 U.K.. Fig. 64 U.K.. psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 65 Germany Fig. 66 Germany psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 67 Spain Fig. 68 Spain psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 69 France Fig. 70 France psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 71 Italy Fig. 72 Italy psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 73 Asia Pacific Fig. 74 Asia Pacific psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 75 Japan Fig. 76 Japan psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 77 China Fig. 78 China psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 79 India Fig. 80 India psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 81 South Korea Fig. 82 South Korea psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 83 Australia Fig. 84 Australia psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 85 Latin America Fig. 86 Latin America psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 87 Brazil Fig. 88 Brazil psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 89 Mexico Fig. 90 Mexico psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 91 Argentina Fig. 92 Argentina psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 93 Middle East and Africa Fig. 94 MEA psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 95 South Africa Fig. 96 South Africa psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 97 Saudi Arabia Fig. 98 Saudi Arabia psoriatic arthritis treatment market, 2014 - 2026 (USD Million) Fig. 99 UAE Fig. 100 UAE Psoriatic psoriatic arthritis market, 2014 - 2026 (USD Million) Fig. 101 Ansoff Matrix Fig. 102 Heat map analysis Fig. 103 Company market share analysis Fig. 104 Company market position analysis Fig. 105 Company market share, by region Fig. 106 Market differentiators Fig. 107 Regional network map
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
